Table 6.
Univariate and multivariate regression analysis to explore independent predictors affecting long-term mortality in sepsis after propensity score matching.
| Parameters | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|
| HR | 95%CI | P | HR | 95%CI | P | |
| Age>65 years | 2.041 | 1.583–2.633 | <0.001 | 2.216 | 1.710–2.874 | <0.001 |
| Weight | 0.998 | 0.993–1.003 | 0.369 | |||
| Gender (male) | 0.890 | 0.705–1.124 | 0.329 | |||
| Race | ||||||
| Race white | 0.837 | 0.653–1.074 | 0.161 | |||
| Race black | 0.706 | 0.432–1.152 | 0.164 | |||
| Race hispanic | 0.330 | 0.106–1.029 | 0.056 | |||
| Race other | 1.712 | 1.309–2.238 | <0.001 | 1.647 | 1.256–2.160 | <0.001 |
| Preexisting medical conditions | ||||||
| Malignancy | 1.859 | 1.465–2.358 | <0.001 | 1.688 | 1.314–2.167 | <0.001 |
| Stroke | 1.282 | 0.702–2.342 | 0.419 | |||
| AFIB | 1.550 | 1.223–1.965 | <0.001 | - | ||
| CAD | 1.178 | 0.904–1.537 | 0.226 | |||
| COPD | 1.228 | 0.858–1.756 | 0.261 | |||
| Renal disease | 1.354 | 1.013–1.809 | 0.041 | |||
| Elixhauser comorbidity index | 1.047 | 1.030–1.064 | <0.001 | |||
| Respiratory rate (>30 beats/min) | 1.340 | 1.062–1.689 | 0.013 | 1.298 | 1.025–1.644 | 0.030 |
| Heart rate (>100 beats/min) | 1.184 | 0.919–1.527 | 0.192 | - | ||
| Laboratory parameters within the first 24 h of ICU admission | ||||||
| INR levels at >1.5 | 1.690 | 1.331–2.147 | <0.001 | 1.325 | 1.031–1.704 | 0.028 |
| Maximum platelet levels (10∧9/L) | ||||||
| Platelet≥ 250 | ||||||
| Platelet at 150~249 | 0.741 | 0.561–0.980 | 0.035 | 0.669 | 0.504–0.887 | 0.005 |
| Platelet at 100~149 | 0.943 | 0.670–1.327 | 0.736 | 0.777 | 0.550–1.097 | 0.777 |
| Platelet at 50~99 | 0.822 | 0.528–1.281 | 0.387 | 0.789 | 0.505–1.233 | 0.789 |
| Platelet at <50 | 1.593 | 0.954–2.659 | 0.075 | 1.787 | 1.047–3.048 | 0.033 |
| Maximum lactate levels(mmol/L) | ||||||
| Lactate at 0–2 | ||||||
| Lactate at 2.1–4 | 1.227 | 0.905–1.663 | 0.189 | 1.107 | 0.813–1.507 | 0.518 |
| Lactate at 4.1–10 | 1.715 | 1.264–2.328 | 0.001 | 1.435 | 1.042–1.977 | 0.027 |
| Lactate at >10 | 4.990 | 3.354–7.423 | <0.001 | 3.976 | 2.586–6.112 | <0.001 |
| Maximum Bicarbonate levels | - | |||||
| Bicarbonate levels at 22–29 | ||||||
| Bicarbonate levels at <22 | 1.982 | 1.555–2.526 | <0.001 | 1.536 | 1.192–1.980 | 0.001 |
| Bicarbonate levels at >29 | 1.487 | 0.970–2.279 | 0.068 | 1.767 | 1.147–2.725 | 0.010 |
| AKI KDIGO stage | ||||||
| AKI at 1 stage | 0.921 | 0.638–1.328 | 0.659 | |||
| AKI at 2 stage | 1.600 | 1.177–2.174 | 0.003 | |||
| AKI at 3 stage | 1.868 | 1.346–2.593 | <0.001 | |||
| Mechanical ventilation | 1.459 | 1.155–1.845 | 0.002 | |||
| Sedative drug usage | 1.293 | 1.025–1.631 | 0.030 | |||
| The use of vasoactive drug | 1.447 | 1.148–1.824 | 0.002 | |||
| Serum total bilirubin levels during the course of disease (mg/dL) | ||||||
| Serum total bilirubin < 5 mg/dL | ||||||
| Serum total bilirubin at ≥ 5 mg/dL | 1.776 | 1.370–2.301 | <0.001 | 1.608 | 1.228–2.106 | 0.001 |
CHF congestive heart failure, AFIB atrial fibrillation, CAD coronary artery disease, COPD chronic obstructive pulmonary disease, SOFA Sequential Organ Failure Assessment. AKI acute kidney injury, KDIGO the Kidney Disease: Improving Global Outcomes.